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Based on a study conducted by the WHO Global Burden of Disease in 2010 stated, OA ranks 
11th, the cause of disability in the world, and ranks 6th in East Asia and the Asia-Pacific 
countries, ranked 10th in North America, ranked 7th in Eastern Europe , and ranked 13th in 
Western Europe. Pathogenesis of osteoarthritis (OA) as degenerative joint disease that was once 
thought caused by a mechanical process. The prevalence, etiology, pathogenesis and progression 
of OA are still not understood until now, mainly because of the many influencing factors. This 
type of research is a analytic study. It was conducted in Rheumatology Polyclinic Dr. 
Mohammad Hoesin Palembang from February to December 2019. Affordable research 
population is all genu osteoarthritis sufferers with effusion who go to Dr. RSUP Mohammad 
Hoesin Palembang as 80 samples. Comparison of NFATC1 mRNA levels in genu osteoarthritis 
patients with effusion shows that there is no difference in gender and history of diabetes, whereas 
hypertension history and degree of osteoarthritis based on Lawrence Kalgren shows significantly 
different expression of NFATC1 mRNA. Age with NFATC1 mRNA expression showed no 
significant correlation, in contrast to BMI, Stroke Test and joint effusion volume showed a weak 
significant correlation, even though the direction of the correlation was negative on Stroke Test 
and joint effusion volume. 
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Introduction 
Osteoarthritis (OA) is a degenerative joint disease that was once thought to be a pathogenesis 
caused by a mechanical process. The prevalence, etiology, pathogenesis and progression of OA 
are still not understood until now, mainly because of the many influencing factors. Without clear 
evidence of the cellular and molecular mechanisms that occur in OA, many opinions state that 
OA is considered a wear and tear process and the consequences of the aging process. Based on a 
study conducted by the WHO Global Burden of Disease in 2010 stated, OA ranks 11th, the cause 
of disability in the world, and ranks 6th in East Asia and the Asia-Pacific countries, ranked 10th 
in North America, ranked 7th in Eastern Europe , and ranked 13th in Western Europe. Nuclear 
Factor Activated T cell 1 (NFATC1) is a protein coding gene, which is part of the Nuclear Factor 
Activated T Cell (NFAT) group. NFAT is a group of transcription factors that are important in 
the body's immune response. Most of the form of NFAT is expressed in the body's immune cells. 
NFAT currently has an important role in regulating various systems in the body. NFATC1 is 
regulated by calcium signaling, which activates calmodulin (CaM) and serine / threonin 
phosphatease calcineurin (CN), so that NFATC1 is active and can enter the nucleus, which then 
occupies gene promoters that can activate the transcription of the gene to produce a protein. 
specifics that are important for regulating systems in the body. The process of gene transcription 
will produce Messanger Ribonucleic Acid (mRNA) IL-1β. Research that analyzes the 
involvement of the NFATC1 gene in OA genu with effusion has never been done before, so data 
on gene expression and cytokines have not been published. Therefore, researchers are interested 
in knowing the expression of NFATC1 mRNA in patients with genu osteoarthritis effusion. 
 
Methods 
This type of research is a analytic study. It was conducted at the Rheumatology Polyclinic Dr. 
Mohammad Hoesin Palembang from February to December 2019. Affordable research 
population is all genu osteoarthritis sufferers with effusion who go to Dr. RSUP Mohammad 
Hoesin Palembang. Inclusion Criteria : Genu osteoarthritis sufferers with effusion who have 
 
been diagnosed based on 2010 American College of Rheumatology Criteria and Genu 
osteoarthritis sufferers with effusion whose aspiration of joint fluid has positive results. Patient 
willing to participate in research and sign informed consent. Exclusion Criteria :Genu effusion 
due to trauma, malignancy, autoimmune diseases (Systemic Lupus Erythematosus, Rheumatoid 
Arthritis), gouty arthritis, septic arthritis, refuse to take part in research. This research subjects 
using total sampling. All subjects who came for treatment from April 2019 to October 2019, who 
met the inclusion criteria were included in the study. Research variable: NFATC1 mRNA, the 
degree of effusion of OA genu, Age, sex, hypertension, diabetes mellitus, BMI. NFATC1 
(nuclear factor activated T cell 1) is a protein coding gene. NFATC1 is a form of isoform of the 
NFAT (nuclear factor activated T) gene group. NFAT is a group of transcription factors that are 
important in the body's immune response. With Reverse Transcription Polymerase Chain 
Reaction (RT PCR) which goes through three stages namely RNA extraction, PCR, and 
Electrophoresis Obtained NFATC1 mRNA expression in units of A.U. 
 
Results 
The largest group of women is around two thirds of the entire study sample, compared to the 
male group. The level of education is almost mostly tertiary education, compared to the 
secondary education group, namely junior high and high school, and low education which is only 
11%. Patients occupations are mostly housewives, followed by state, private, peasant and teacher 
civil servants. The mean age of the patients was 59.4 ± 13.4 years which showed the age group 
as a risk factor for degenerative diseases.  
 
Table 1. Characteristics of physical examination of genu osteoarthritis patients with effusion 
No. History Subject (n=80 ) 
1 Diabetes Melitus  
 Yes 5% 
 No  95% 
2 Hypertension  
 Yes 27,5% 
 No 72,5% 
 
 
Table 1 shows the history of diabetes mellitus and hypertension in genu osteoarthritis patients 
with effusion. Most showed no history of DM, but only a quarter had a history of hypertension. 
BMI of patients in this study showed more weight categories based on Asia Pacific BMI 
categories.  
 
Table 2. Characteristics of physical examination of genu osteoarthritis patients with effusion 
No. Variabel Subject (n=80 ) 
1 BMI (kg/m2), Mean ± SD 24,9 ± 6,2 
2 Volume Effusion (mL), Mean ± SD 14,9 ± 5,3 
 
The volume of joint fluid aspirated in genu osteoarthritis patients was found to be 14.9 ± 5.3 mL. 
Characteristics of physical examination on genu effusion (table 3) show that most of them get a 
score of 2 based on the Stroke Test Score. 
 
Table 3. Characteristics of effusion tests in genu osteoarthritis patients 
Stroke Test Score Subject (n=80 ) 
Score 1 25% 
Score 2 62,5% 
Score 3 12,5% 
 
Radiological investigations based on Kallgren-Lawrence in genu osteoarthritis patients with 
effusions showed grade 3 and 4 results with percentages that did not differ much (table 4). 
 
Table 4. Characteristics of kallgren-lawrence radiological investigations in genu osteoarthritis 
patients with effusion 
Kallgren-Lawrence Subject (n=80 ) 
Grade 3 45% 
Grade 4 55% 
 
 
Laboratory investigations showed that LED results did not increase and qualitative CRP was 
largely negative. The results of NFATC1 levels were 67.8 ± 12.8 pg / mL. 
 
Table 5. Characteristics of laboratory examinations of genu osteoarthritis patients with effusion 
No. Variabel Subject (n=80 ) 
1. ESR (mm/hr), Mean ± SD 10,2 ± 2,1 
2. CRP Qualitative  
 Positive 0 
 Negative 100% 
3. NFATC1 (pg/mL), Mean ± SD 67,8 ± 12.8 
 
Comparison of NFATC1 mRNA levels in genu osteoarthritis patients with effusion shows that 
there is no difference in sex and history of diabetes, whereas hypertension history and degree of 
osteoarthritis based on Lawrence Kalgren shows significantly different expression of NFATC1 
mRNA. This is probably due to the large number of patients who have a history of hypertension, 
which is about 27.5% of the 80 samples from this study, as well as both grades on the Lawrence 
Kalgren, the number of samples participating is almost equal. 
 





1.  Gender  0,615 
 Man 0,66 (±0,531)  
 Women 0,53(±0,386)  
2. Diabetes Melitus  0,456 
 No 0,55 (±0,405)  
 Yes 0,80 (±0,724)  
3. Hypertension  0,015 
 No 0,50 (±0,411)  
 Yes 0,70 (±0,429)  
4. Kalgren Lawrence  0,010 
 Grade 3 0,68 (±0,482)  
 Grade 4 0,45 (±0,335)  
 
 
Table 7. Correlation of patient characteristics with NFATC1 mRNA in patients with genu 
osteoarthritis with effusion 
No. Variable mRNA NFATC1 
1. Usia p = 0.201 
 
 r = -0.145 
2. BMI p = 0.032 
 
 r = 0.239 
3. Stroke Test p = 0.003 
 
 r = -0.333 
4. Efusi Sendi p = 0.000 
 
 r = -0.472 
 
Age with NFATC1 mRNA expression showed no significant correlation, in contrast to BMI, 
Stroke Test and joint effusion volume showed a weak significant correlation, although the 
direction of the correlation was negative on Stroke Test and joint effusion volume. An increase 
in patient BMI shows an increase in NFATC1 mRNA expression with weak correlation strength. 
Conversely, an increase in stroke test and joint effusion volume will reduce NFATC1 mRNA 
expression with weak correlation strength. 
 
Discussion 
In osteoarthritis, activation of catabolic enzymes such as matrix metalloproteinases (MMPs) and 
aggrecan will cause softening of the articular cartilage. Increased levels of IL-1β can stimulate 
catabolic enzyme expression and induce peripheral cartilage and articular cartilage bone 
transformation. There are studies evaluating the levels of NFAT1, IL-1β, TNF-α in articular 
cartilage in osteoarthritis patients and healthy people using western blot analysis. The results of 
the study revealed that the expression of NFAT1, IL-1β, TNF-α would increase in cartilage 
tissue in osteoarthritis patients. In chondrocyte cells with inactive NFAT1 levels, low IL-1β and 
MMP levels were obtained. There is a Calcineurin-NFAT pathway that plays a role in 
osteoarthritis. But data on the role of calcineurin-NFAT in cartilage metabolism and 
osteoarthritis are still very limited. 
 
 
Based on a meta-analysis study conducted by Peters, MJ, Ramos, YFM, et al, 2016 regarding the 
association between joint effusion and in the knee and gene expression in levels in the circulation 
states that there is a correlation between the severity of joint effusion degree and the high 
expression of NFATC1 (nuclear factor of activated T cells 1). Besides functioning in the process 
of bone remodeling through calcium or calcineurin signals, NFATC1 has a central role in 
inducing genes that play a role in the immune system. Although there were no differences in the 
expression of NAFTC1 in cartilage tissue with osteoarthritis and no osteoarthritis by microarrays 
analysis, detection on RT-qPCR showed a significant reduction in the amount of cartilage 
affected by osteoarthritis. In this studies may differ many factors that influence the expression of 
NFATC1 mRNA such as therapy and duration of illness, which were not examined in this study. 
 
Conclusion 
Comparison of NFATC1 mRNA levels in genu osteoarthritis patients with effusion shows that 
there is no difference in gender and history of diabetes, whereas hypertension history and degree 
of osteoarthritis based on Lawrence Kalgren shows significantly different expression of 
NFATC1 mRNA. Age with NFATC1 mRNA expression showed no significant correlation, in 
contrast to BMI, Stroke Test and joint effusion volume showed a weak significant correlation, 
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